Biotest GmbH & Co. KGaA (HAM:BIO1)

Germany · Delayed Price · Currency is EUR

42.40

+3.20 (8.16%)

Inactive · Last trade price on May 21, 2026

Market Cap	1.48B
Revenue (ttm)	635.20M -18.8%
Net Income	-24.50M
EPS	-0.63
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59
Open	39.20
Previous Close	39.20
Day's Range	39.20 - 42.40
52-Week Range	33.00 - 45.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 30, 2026

About Biotest GmbH & Co. KGaA

Biotest GmbH & Co. KGaA develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin SDH and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company also offers Cytotect CP biotest for prophylaxis of the clinical manifestation of cytomegalov... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1946

Employees 2,495

Stock Exchange Hamburg Stock Exchange

Ticker Symbol BIO1

Financial Performance

In 2024, Biotest GmbH & Co. KGaA's revenue was 726.20 million, an increase of 6.08% compared to the previous year's 684.60 million. Earnings were 26.40 million, a decrease of -79.21%.

Financial Statements